FMR LLC sold $10.0M of BEAM (indirect holdings)

FMR LLC sold 284,860 indirectly-held shares of Beam Therapeutics Inc. (BEAM) at an average of $35.24 ($35.12–$35.26, $10.04M total) across 2 trades over 2026-06-25 to 2026-06-26.

Original reporting
SEC EDGAR · FMR LLC
Published Jun 29, 2026, 6:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 29, 2026, 6:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BEAM
Bearish
medium confidence
Mentioned
$BEAM
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BEAMBearishLow
01

Why it matters

Traders may treat this as a modest negative sentiment input for BEAM, but it does not introduce new clinical, regulatory, or financial guidance.

02

Market read

A fresh $10.04M open-market sale by a 10% owner is disclosed today, which can influence short-term positioning and sentiment around BEAM.

03

What to watch

No 10b5-1 plan is indicated; however, the transactions occurred over two days (6/25–6/26) and the filing alone doesn’t confirm intent or future selling pace.

Relevance 7/10Novelty 6/10Timing: today’s SEC Form 4 filing (filed 2026-06-29)

Background

The article is an SEC Form 4 insider transaction disclosure: FMR LLC (a 10% owner) sold Beam Therapeutics shares indirectly via open-market sales.

Company-level read

Ticker impact

$BEAMBearishMedium confidence
Context

FMR LLC filed a Form 4 selling 284,860 Beam Therapeutics shares in open-market transactions totaling about $10.04M.

Expected impact

Near-term sentiment could soften; magnitude likely limited because it’s an SEC Form 4 sale without accompanying fundamental news.

Evidence & confidence

This is a primary-source transaction print (new today) with clear size ($10.04M) and role (10% owner), but it lacks a stated reason, 10b5-1 plan, or linkage to operational updates.

Market effects

Limited read-through to biotech broadly; this is a single-company ownership transaction without sector-wide catalyst.

No clear regional spillover indicated by the filing details.

Minimal global relevance; transaction is specific to Beam Therapeutics holdings.

Counterpoint

The sale could be routine liquidity management rather than a bearish view, especially since the filing does not provide a thesis or link to performance.

Key entities

  • Beam Therapeutics Inc.

    Issuer of the Form 4; subject of the reported insider sale.

  • FMR LLC

    Reporter; 10% owner conducting indirect open-market sales.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BEAMHighAI 9/10

Beam Sickle Cell Therapy Meets Pivotal Goals

Beam Therapeutics reported positive pivotal trial results for risto-cel, its sickle cell treatment, meeting all primary and secondary endpoints. The trial showed patients stayed free of severe vaso-occlusive crises for at least 12 months. Beam plans to file for FDA approval by year-end 2026, aiming to be the first base-editing therapy approved in the US. The company will present detailed results at a medical meeting in 2027.